The Meth Treatment Gap

Methamphetamine use disorder is one of the most undertreated conditions in American healthcare. Not because clinicians lack empathy or effort — but because the pharmacological toolkit that transformed opioid care over the last two decades simply does not exist for stimulants.

There is currently no FDA-approved medication for methamphetamine use disorder. While people with opioid use disorder can access buprenorphine, methadone, or naltrexone within days of seeking help, a person struggling with methamphetamine today is offered behavioral therapy, peer support, and hope. That gap matters: methamphetamine-involved overdose deaths have more than tripled since 2015, driven in large part by the simultaneous rise of fentanyl co-contamination in the stimulant supply.

Why the Pharmacology Is So Difficult

Opioid use disorder has a clean mechanistic target: the mu-opioid receptor. Methamphetamine acts through an entirely different and far more diffuse pathway, flooding dopamine, norepinephrine, and serotonin systems simultaneously. There is no equivalent approach. Researchers have tested more than two dozen medication candidates over the past fifteen years with inconsistent results.

The Contingency Management Problem

The most evidence-backed treatment for stimulant use disorder is contingency management (CM), a behavioral intervention that offers people small, tangible incentives for verified abstinence or attendance. A study of syringe service program participants found that 82.8% expressed interest in CM to reduce or stop stimulant use.

Federal policy has effectively capped incentive amounts at token levels — far below what the evidence suggests is therapeutically effective. The result: the most effective behavioral treatment for meth is available in a fraction of the programs that could use it.

What the Medication Pipeline Shows

A Phase III NIH trial of injectable naltrexone combined with oral bupropion found the combination was safe and effective in adults with moderate-to-severe methamphetamine use disorder. Early-stage work on GLP-1 receptor agonists is also underway; a BMJ study of 600,000+ US veterans found that people taking GLP-1 medications had a 14–25% lower risk of developing stimulant use disorders.

Harm Reduction Under Pressure

The federal harm reduction rollback of 2026 lands particularly hard on communities with high methamphetamine use. SAMHSA’s April 24 Dear Colleague letter withdrew federal eligibility for safer smoking supplies — used by people who smoke methamphetamine. With co-contamination of the meth supply by fentanyl a documented reality, losing access to test strips removes a life-saving layer of protection.

Why This Matters for People in Recovery

If you or someone you care about is struggling with methamphetamine, understanding the treatment landscape means knowing what to ask for: access to contingency management, peer support from someone with lived stimulant recovery experience, and a provider familiar with the off-label combination pharmacotherapy evidence.

Find treatment options near you, including programs with contingency management, at Rize Recovery.